Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
DVA's Cash-to-Debt is ranked lower than
62% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. DVA: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
DVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.12 Max: N/A
Current: 0.2
Equity-to-Asset 0.27
DVA's Equity-to-Asset is ranked lower than
79% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. DVA: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
DVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35  Med: 0.25 Max: 0.7
Current: 0.27
-0.35
0.7
Interest Coverage 5.81
DVA's Interest Coverage is ranked lower than
61% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.41 vs. DVA: 5.81 )
Ranked among companies with meaningful Interest Coverage only.
DVA' s Interest Coverage Range Over the Past 10 Years
Min: 2.87  Med: 4.46 Max: 5.81
Current: 5.81
2.87
5.81
Piotroski F-Score: 7
Altman Z-Score: 2.13
Beneish M-Score: -2.73
WACC vs ROIC
6.28%
13.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 16.27
DVA's Operating Margin % is ranked higher than
77% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. DVA: 16.27 )
Ranked among companies with meaningful Operating Margin % only.
DVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.49  Med: 15.37 Max: 17.15
Current: 16.27
8.49
17.15
Net Margin % 8.28
DVA's Net Margin % is ranked higher than
67% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. DVA: 8.28 )
Ranked among companies with meaningful Net Margin % only.
DVA' s Net Margin % Range Over the Past 10 Years
Min: 1.96  Med: 6.54 Max: 8.28
Current: 8.28
1.96
8.28
ROE % 25.47
DVA's ROE % is ranked higher than
90% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 9.35 vs. DVA: 25.47 )
Ranked among companies with meaningful ROE % only.
DVA' s ROE % Range Over the Past 10 Years
Min: 5.37  Med: 19.11 Max: 25.64
Current: 25.47
5.37
25.64
ROA % 6.53
DVA's ROA % is ranked higher than
67% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. DVA: 6.53 )
Ranked among companies with meaningful ROA % only.
DVA' s ROA % Range Over the Past 10 Years
Min: 1.49  Med: 4.95 Max: 6.53
Current: 6.53
1.49
6.53
ROC (Joel Greenblatt) % 72.91
DVA's ROC (Joel Greenblatt) % is ranked higher than
84% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 16.07 vs. DVA: 72.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 38.04  Med: 56.82 Max: 72.91
Current: 72.91
38.04
72.91
3-Year Revenue Growth Rate 9.50
DVA's 3-Year Revenue Growth Rate is ranked higher than
57% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. DVA: 9.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.8  Med: 12.7 Max: 44.8
Current: 9.5
4.8
44.8
3-Year EBITDA Growth Rate 9.70
DVA's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. DVA: 9.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -38.6  Med: 15 Max: 98.2
Current: 9.7
-38.6
98.2
3-Year EPS without NRI Growth Rate 14.10
DVA's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 7.50 vs. DVA: 14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29  Med: 14.1 Max: 125.5
Current: 14.1
-29
125.5
GuruFocus has detected 3 Warning Signs with DaVita Inc $DVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

DVA Guru Trades in Q2 2016

Ray Dalio 75,970 sh (+1051.06%)
Andreas Halvorsen 4,611,729 sh (+164.36%)
Jim Simons 1,376,800 sh (+26.14%)
Warren Buffett 38,565,570 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli 40,363 sh (-2.89%)
Manning & Napier Advisors, Inc 1,375,595 sh (-28.03%)
Arnold Van Den Berg 79,300 sh (-75.89%)
» More
Q3 2016

DVA Guru Trades in Q3 2016

Joel Greenblatt 45,595 sh (New)
Warren Buffett 38,565,570 sh (unchged)
Andreas Halvorsen Sold Out
Manning & Napier Advisors, Inc 1,354,745 sh (-1.52%)
Arnold Van Den Berg 77,285 sh (-2.54%)
Jim Simons 1,313,500 sh (-4.60%)
Ray Dalio 65,300 sh (-14.05%)
Mario Gabelli 32,613 sh (-19.20%)
» More
Q4 2016

DVA Guru Trades in Q4 2016

Steven Cohen 283,200 sh (New)
Richard Pzena 3,327 sh (New)
Joel Greenblatt 440,617 sh (+866.37%)
Ray Dalio 88,244 sh (+35.14%)
Warren Buffett 38,565,570 sh (unchged)
Arnold Van Den Berg Sold Out
Mario Gabelli 21,663 sh (-33.58%)
Jim Simons 844,500 sh (-35.71%)
Manning & Napier Advisors, Inc 288,580 sh (-78.70%)
» More
Q1 2017

DVA Guru Trades in Q1 2017

Paul Tudor Jones 461,620 sh (New)
Andreas Halvorsen 381,597 sh (New)
Leucadia National 7,135 sh (New)
Ray Dalio 142,304 sh (+61.26%)
Jim Simons 1,192,900 sh (+41.26%)
Mario Gabelli 22,163 sh (+2.31%)
Warren Buffett 38,565,570 sh (unchged)
Richard Pzena 3,327 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 357,208 sh (-18.93%)
Manning & Napier Advisors, Inc 172,000 sh (-40.40%)
» More
» Details

Insider Trades

Latest Guru Trades with DVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621492    SIC: 8092
Compare:NYSE:UHS, NAS:WOOF, NYSE:EVHC, NYSE:MD, NAS:ACHC, NYSE:HLS, NYSE:CHE, NAS:LPNT, NYSE:SEM, NAS:AMED, NYSE:THC, NYSE:AMN, NAS:TVTY, NAS:LHCG, NYSE:CYH, NAS:SGRY, NAS:AFAM, NYSE:USPH, NAS:PRSC, NAS:ADUS » details
Traded in other countries:TRL.Germany,
Headquarter Location:USA
DaVita Inc is engaged in operating kidney dialysis centers and providing related lab services in dialysis centers and in contracted hospitals across USA. It also operates other ancillary services and strategic initiatives.

DaVita is the world's second-largest dialysis provider, with most of its 2,400 clinics based in the U.S. The company treats nearly 200,000 patients with end-stage renal disease. In a 2012 deal valued at nearly $4.4 billion, DaVita merged with HealthCare Partners, one of the largest physician group managers in the U.S., which now represents approximately 25% of consolidated revenue. HCP coordinates care for nearly 800,000 members with a network of thousands of physicians and specialists in California, Florida, Nevada, New Mexico, and Arizona.

Top Ranked Articles about DaVita Inc

DaVita Medical Group Acquires Respected Physician Practices in the Orlando Area
Warren Buffett’s 5 Highest-Quality Companies Higher quality corresponds with higher return
Warren Buffett (Trades, Portfolio) preaches the “high-quality, fair-price” theory of value investing. Buying good companies with reasonable price tags has been more profitable for him, he has said, than his earlier approach of trying to find fair companies cheap. His portfolio, therefore, should showcase a host of these. But which are the best? Read more...
Dr. David Mahoney Named Chief Medical Officer of Lifeline Vascular Access
DaVita Clinical Research Launches Alliance Site Network for Early Stage CKD Trials
Buffett's Deputies Weschler and Combs See Mostly Gains in First Half Most stocks up, though some trail S&P 500
A great deal of Berkshire’s future rests on whether Buffett picks people as well as stocks. So far, he has seemed unflaggingly confident in the two he hired to eventually lead investing, Ted Weschler and Todd Combs. Their performance this year should also make Berkshire investors happy. Most of the stocks reportedly owned by the two have risen or soared above the S&P 500, including the airlines stocks Buffett said were “in large part” his decision. Read more...
DaVita Celebrates 10 Years of Sustainability
DaVita Introduces DaVita® Health Solutions
HealthCare Partners to Acquire Magan Medical Clinic
DaVita Celebrates Military Appreciation Month
DaVita Kidney Care Welcomes Eric Severson as Chief People Officer

Ratios

vs
industry
vs
history
PE Ratio 10.86
DVA's PE Ratio is ranked higher than
92% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 26.05 vs. DVA: 10.86 )
Ranked among companies with meaningful PE Ratio only.
DVA' s PE Ratio Range Over the Past 10 Years
Min: 10.36  Med: 18.25 Max: 58.72
Current: 10.86
10.36
58.72
Forward PE Ratio 18.21
DVA's Forward PE Ratio is ranked higher than
69% of the 62 Companies
in the Global Medical Care industry.

( Industry Median: 21.05 vs. DVA: 18.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 10.86
DVA's PE Ratio without NRI is ranked higher than
93% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. DVA: 10.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
DVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.36  Med: 18.16 Max: 58.72
Current: 10.86
10.36
58.72
Price-to-Owner-Earnings 7.56
DVA's Price-to-Owner-Earnings is ranked higher than
91% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 27.37 vs. DVA: 7.56 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.22  Med: 16.53 Max: 668.7
Current: 7.56
7.22
668.7
PB Ratio 2.52
DVA's PB Ratio is ranked higher than
52% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 2.54 vs. DVA: 2.52 )
Ranked among companies with meaningful PB Ratio only.
DVA' s PB Ratio Range Over the Past 10 Years
Min: 2.25  Med: 3.19 Max: 5.3
Current: 2.52
2.25
5.3
PS Ratio 0.90
DVA's PS Ratio is ranked higher than
77% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. DVA: 0.90 )
Ranked among companies with meaningful PS Ratio only.
DVA' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.15 Max: 1.45
Current: 0.9
0.77
1.45
Price-to-Free-Cash-Flow 8.72
DVA's Price-to-Free-Cash-Flow is ranked higher than
90% of the 116 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. DVA: 8.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.51  Med: 15.34 Max: 42.42
Current: 8.72
7.51
42.42
Price-to-Operating-Cash-Flow 5.55
DVA's Price-to-Operating-Cash-Flow is ranked higher than
91% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 15.16 vs. DVA: 5.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.2  Med: 8.9 Max: 15.89
Current: 5.55
5.2
15.89
EV-to-EBIT 8.40
DVA's EV-to-EBIT is ranked higher than
93% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 20.05 vs. DVA: 8.40 )
Ranked among companies with meaningful EV-to-EBIT only.
DVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 11.8 Max: 20.3
Current: 8.4
6.8
20.3
EV-to-EBITDA 6.44
DVA's EV-to-EBITDA is ranked higher than
92% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 15.41 vs. DVA: 6.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 9.3 Max: 14.4
Current: 6.44
5.5
14.4
PEG Ratio 1.29
DVA's PEG Ratio is ranked higher than
80% of the 98 Companies
in the Global Medical Care industry.

( Industry Median: 3.06 vs. DVA: 1.29 )
Ranked among companies with meaningful PEG Ratio only.
DVA' s PEG Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.45 Max: 5.59
Current: 1.29
0.4
5.59
Shiller PE Ratio 23.49
DVA's Shiller PE Ratio is ranked higher than
63% of the 51 Companies
in the Global Medical Care industry.

( Industry Median: 29.00 vs. DVA: 23.49 )
Ranked among companies with meaningful Shiller PE Ratio only.
DVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.65  Med: 29.67 Max: 58.5
Current: 23.49
19.65
58.5
Current Ratio 1.64
DVA's Current Ratio is ranked higher than
60% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. DVA: 1.64 )
Ranked among companies with meaningful Current Ratio only.
DVA' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.86 Max: 5.97
Current: 1.64
0.39
5.97
Quick Ratio 1.57
DVA's Quick Ratio is ranked higher than
62% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. DVA: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
DVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.37  Med: 1.8 Max: 5.97
Current: 1.57
0.37
5.97
Days Inventory 6.29
DVA's Days Inventory is ranked higher than
81% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 15.65 vs. DVA: 6.29 )
Ranked among companies with meaningful Days Inventory only.
DVA' s Days Inventory Range Over the Past 10 Years
Min: 3.72  Med: 6 Max: 8.61
Current: 6.29
3.72
8.61
Days Sales Outstanding 46.68
DVA's Days Sales Outstanding is ranked lower than
56% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. DVA: 46.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.53  Med: 62.54 Max: 69.35
Current: 46.68
43.53
69.35
Days Payable 15.73
DVA's Days Payable is ranked lower than
81% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 44.51 vs. DVA: 15.73 )
Ranked among companies with meaningful Days Payable only.
DVA' s Days Payable Range Over the Past 10 Years
Min: 14.92  Med: 19.24 Max: 27.07
Current: 15.73
14.92
27.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.00
DVA's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. DVA: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.4  Med: -0.8 Max: 9.3
Current: 3
-58.4
9.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.71
DVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
91% of the 97 Companies
in the Global Medical Care industry.

( Industry Median: 1.97 vs. DVA: 0.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.7  Med: 1.16 Max: 13.33
Current: 0.71
0.7
13.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.90
DVA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
86% of the 36 Companies
in the Global Medical Care industry.

( Industry Median: 1.65 vs. DVA: 0.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.78
DVA's Price-to-Median-PS-Value is ranked higher than
81% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. DVA: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.08 Max: 5.28
Current: 0.78
0.16
5.28
Price-to-Peter-Lynch-Fair-Value 1.26
DVA's Price-to-Peter-Lynch-Fair-Value is ranked higher than
75% of the 59 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. DVA: 1.26 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DVA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.3 Max: 8.16
Current: 1.26
0.46
8.16
Earnings Yield (Greenblatt) % 11.89
DVA's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.84 vs. DVA: 11.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.9  Med: 8.5 Max: 14.6
Current: 11.89
4.9
14.6
Forward Rate of Return (Yacktman) % 15.80
DVA's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: 10.98 vs. DVA: 15.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.5  Med: 19.5 Max: 35.4
Current: 15.8
12.5
35.4

More Statistics

Revenue (TTM) (Mil) $14,861.25
EPS (TTM) $ 6.12
Beta1.07
Short Percentage of Float3.83%
52-Week Range $54.50 - 78.40
Shares Outstanding (Mil)194.60

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 15,279 16,102
EPS ($) 3.57 3.85
EPS without NRI ($) 3.57 3.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.95%
Dividends per Share ($)
» More Articles for DVA

Headlines

Articles On GuruFocus.com
DaVita Medical Group Acquires Respected Physician Practices in the Orlando Area Jul 13 2017 
Warren Buffett’s 5 Highest-Quality Companies Jun 23 2017 
Dr. David Mahoney Named Chief Medical Officer of Lifeline Vascular Access Jun 19 2017 
DaVita Clinical Research Launches Alliance Site Network for Early Stage CKD Trials Jun 15 2017 
Buffett's Portfolio Managers Weschler and Combs Enjoy Solid Year So Far Jun 14 2017 
DaVita Celebrates 10 Years of Sustainability Jun 08 2017 
DaVita Introduces DaVita® Health Solutions Jun 06 2017 
HealthCare Partners to Acquire Magan Medical Clinic Jun 01 2017 
3 Magic Formula Stocks Ready to Move Up Jun 01 2017 
DaVita Celebrates Military Appreciation Month May 25 2017 

More From Other Websites
DaVita, Inc. breached its 50 day moving average in a Bullish Manner : DVA-US : July 18, 2017 Jul 18 2017
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando Jul 14 2017
DaVita Medical Group Acquires Respected Physician Practices in the Orlando Area Jul 13 2017
Robbins Arroyo LLP Investigates Whether DaVita Inc. (DVA) Misled Shareholders Jul 07 2017
DaVita Inc. Schedules 2nd Quarter 2017 Investor Conference Call Jul 05 2017
DaVita Medical Group Recognized for Excellence in Coordinated Care Jun 29 2017
Patient-Steering Allegations Only One Reason DaVita Shares Getting Downgraded Jun 26 2017
DaVita Banks on Acquisitions, Escalating Expenses a Concern Jun 26 2017
Morning Movers: Arconic Tumbles, DaVita Drops, Coach Rises Jun 26 2017
Investigation Relating to 401(k) Plans of DaVita Inc. (NYSE:DVA) Commenced by Stull, Stull & Brody Jun 23 2017
Warren Buffett's 5 Highest-Quality Companies Jun 23 2017
Is DaVita a Suitable Stock for Value Investors? Jun 20 2017
ETFs with exposure to DaVita, Inc. : June 19, 2017 Jun 19 2017
Dr. David Mahoney Named Chief Medical Officer of Lifeline Vascular Access Jun 19 2017
DBJ's best of the week for June 10-16: Inside the Amazon and ViaWest deals, hospital merger talks... Jun 16 2017
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial Jun 16 2017
Health-Care Investors Are in Denial Jun 16 2017
DaVita Clinical Research Launches Alliance Site Network for Early Stage CKD Trials Jun 15 2017
Buffett's Deputies Weschler and Combs See Mostly Gains in First Half Jun 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}